Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Merck
Mallinckrodt
Colorcon
Harvard Business School

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR ESTROGENS, CONJUGATED


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Estrogens, Conjugated

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000419 ↗ Safety of Estrogens in Lupus: Hormone Replacement Therapy Terminated National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1996-04-01 Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗ Safety of Estrogens in Lupus: Hormone Replacement Therapy Terminated Office of Research on Women's Health (ORWH) Phase 3 1996-04-01 Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗ Safety of Estrogens in Lupus: Hormone Replacement Therapy Terminated New York University School of Medicine Phase 3 1996-04-01 Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000419 ↗ Safety of Estrogens in Lupus: Hormone Replacement Therapy Terminated NYU Langone Health Phase 3 1996-04-01 Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
NCT00000430 ↗ Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis Terminated National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1999-10-01 Osteoporosis, a condition in which bones are fragile and break easily, is a major health problem for postmenopausal women. Research studies have shown that both estrogen/progestin replacement therapy (hormone replacement therapy, or HRT) and alendronate are effective in preventing and treating osteoporosis. However, because these drugs work in somewhat different ways, a combination of the two drugs might protect women from osteoporosis better than either drug alone. In this study we will test whether HRT and alendronate given together for 3.5 years to postmenopausal women with low bone mass will have a greater effect on bone than either HRT or alendronate given alone. We will also give every participant in this study calcium and vitamin D supplements.
NCT00000466 ↗ Postmenopausal Estrogen/Progestin Interventions (PEPI) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1987-09-01 To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Estrogens, Conjugated

Condition Name

Condition Name for Estrogens, Conjugated
Intervention Trials
Menopause 13
Osteoporosis 9
Postmenopause 8
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Estrogens, Conjugated
Intervention Trials
Osteoporosis 9
Breast Neoplasms 6
Lupus Erythematosus, Systemic 3
Atrophy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Estrogens, Conjugated

Trials by Country

Trials by Country for Estrogens, Conjugated
Location Trials
United States 359
Australia 3
Brazil 3
Colombia 3
Mexico 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Estrogens, Conjugated
Location Trials
Pennsylvania 18
California 18
Florida 17
North Carolina 14
Texas 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Estrogens, Conjugated

Clinical Trial Phase

Clinical Trial Phase for Estrogens, Conjugated
Clinical Trial Phase Trials
Phase 4 10
Phase 3 19
Phase 2 10
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Estrogens, Conjugated
Clinical Trial Phase Trials
Completed 41
Terminated 7
Not yet recruiting 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Estrogens, Conjugated

Sponsor Name

Sponsor Name for Estrogens, Conjugated
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 13
Pfizer 10
National Cancer Institute (NCI) 7
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Estrogens, Conjugated
Sponsor Trials
Other 73
Industry 29
NIH 21
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Merck
Baxter
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.